Disease modifying agent related skin reactions in multiple sclerosis: Prevention, assessment, and management

Multiple Sclerosis

Volumn 10, Issue 3, 2004, Pages 302-307

  Frohman, Elliot M ^a   Brannon, K ^a   Alexander, Sherry ^a   Sims, D ^a   Phillips, J T ^b   O'Leary, S ^b   Hawker, K ^a   Racke, M K ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abscess; Erythema; Glatiramer acetate; Interferon beta; Necrosis

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; BETA1A INTERFERON; GABAPENTIN; GLATIRAMER; HYDROCORTISONE; INTERFERON BETA SERINE; LIDOCAINE; SELENIUM; STEROID;

ADULT; ALOPECIA; ARTICLE; CLINICAL TRIAL; DRUG ERUPTION; DRUG TOLERABILITY; EARLY DIAGNOSIS; ERYTHEMA; FOLLOW UP; HUMAN; LIPOATROPHY; LONG TERM CARE; LYMPHADENOPATHY; MALE; MULTIPLE SCLEROSIS; PAIN; PATIENT COMPLIANCE; PRURITUS; PSORIASIS VULGARIS; RISK REDUCTION; SKIN ABSCESS; SKIN BLEEDING; SKIN BRUISING; SKIN CARE; SKIN EXAMINATION; SKIN GRANULOMA; SKIN INDURATION; SKIN INFECTION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN NECROSIS; SKIN ULCER; UNITED STATES; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; ERYTHEMA; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NECROSIS; PEPTIDES; SKIN; SKIN DISEASES;

EID: 3042694842     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1002oa     Document Type: Article

References (15)

1. Frohman EM, Phillips JT, Kokel K, Van Pelt JD, O'Leary S, Gross S, Hawker K, Racke MK. Disease management strategies for multiple scleosis: managing adverse events and optimizing compliance. Neurologist 2002; 8: 227-36.
2. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol 1997; 37: 553-58.
3. Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon β1b injections. J Am Acad Dermatol 1998; 39: 1024-28.
4. Gaines AR, Varricchio F. Interferon beta-1b injection site reactions and necroses. Mult Scler 1998; 4: 70-73.
5. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
6. The IFNβ Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
7. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
8. PRISMS Study Group. PRISMS-4: Ong term efficacy of interferon-β1a in relapsing MS. Neurology 2001; 56: 1628-36.
9. Knobler RL, Kelley CL, Trantas F, Webster GF, Lublin FD. Interferon beta-1b induced ulcerative skin lesions in MS. J Neuroimmunol 1994; 54: 173 (Abstract).
10. Weinberg JM, Wolfe JT, Sood S, Saruk M, Rook AH, Spiers EM. Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. Acta Derm Venerol (Stockh) 1997; 77: 146-48.
11. Quesada JR, Gutterman JU. Psoriasis and interferon alpha. Lancet 1986; 1: 1466 68.
12. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34: 365-67.
13. Betaseron® (interferon beta-1b), prescribing information. Richmond, CA: Berlex Laboratories, July 1993.
14. Drago F, Grusati C, Mancardi G, Murialdo A, Rebora A. Localized lipoatropby after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol 1999; 135: 1277-78.
15. Albani C, Albani G. A case of cutaneous necrosis during interferon-β1b (B-IFN) therapy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 62: 418.